Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial

CHIZURU SAKAI, a MOTOTSUGU SHIMOKAWA, b,c HIROTOSHI IIHARA, d,e YUKIYOSHI FUJITA, f SHINROSUKE ISEMURA, g,h CHIEMI HIROSE, d MIE KOTAKE, i NORIHICO FUNAGUCHI, j TAKEO gOMYO, a HISAO IMAI, l,k JUN HAKAMATA, d DAIZO KAITO, a KOICHI MINATO, f HITOSHI KAWAZOE, m AKIO SUZUKI, d,e YASUSHI OHNO, a HIROYUKI OKURA a

a Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan; b Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan; c Cancer Biostatistics Laboratory, Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka, Japan; d Department of Pharmacy, Gifu University Hospital, Gifu, Gifu, Japan; e Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Gifu, Japan; f Division of Pharmacy, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan; g Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan; h Keio Cancer Center, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan; i Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan; j Department of Respirology, Asahi University Hospital, Gifu, Gifu, Japan; k Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan (present address); l Department of Pharmacy, Keio University Hospital, Shinjuku-ku, Tokyo, Japan; m Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Minato-ku, Tokyo, Japan

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words: Thoracic malignancies • Olanzapine • Carboplatin • Nausea • Vomiting

ABSTRACT

Background. Olanzapine is an inexpensive and durable agent for the treatment of chemotherapy-induced nausea and vomiting and is also superior to neurokinin-1 receptor antagonists in the control of nausea. This study aimed to investigate the efficacy and safety of a low dose of 5 mg olanzapine plus granisetron and dexamethasone for treatment of carboplatin (CBDCA)-induced nausea and vomiting in patients with thoracic malignancies.

Materials and Methods. We conducted a prospective, open-label, single-arm, multicenter, phase II trial in four centers in Japan. Registered patients were scheduled to receive area under the curve (AUC) ≥5 mg/mL per minute of CBDCA and had never received moderately to highly emetogenic chemotherapy. Patients received olanzapine 5 mg/day orally after supper for 4 days, in combination with granisetron and dexamethasone. Primary endpoint was complete response (CR; no emesis and no use of rescue medication) rate during the overall phase (0–120 hours).

Results. Between February 2018 and June 2020, 51 patients were enrolled, and 50 patients were evaluated. The CR rates in the overall (0–120 hours), acute (0–24 hours), and delayed phases (24–120 hours) were 94.0%, 100%, and 94.0%, respectively. No grade 3 or higher adverse effects of olanzapine were observed.

Conclusion. Prophylactic antiemetic therapy with a low dose of 5 mg olanzapine plus granisetron and dexamethasone showed durable efficacy with an acceptable safety profile. This three-drug combination appears to be a reasonable treatment approach in patients with thoracic malignancies receiving an AUC ≥5 mg/mL per minute of CBDCA-based regimen.

Clinical trial identification number: UMIN000031267.

The Oncologist 2021;26:e1066–e1072

Implications for Practice: The results of this phase II trial indicated that the prophylactic administration of low-dose of 5 mg olanzapine combined with granisetron and dexamethasone has promising activity with acceptable safety profile in patients with thoracic malignancy receiving high-dose carboplatin chemotherapy.

Correspondence: Hirotoshi Iihara, Ph.D., 1-1 Yanagido, Gifu, Gifu, 501-1194, Japan. Telephone: 81-58-230-7088; e-mail: dai0920@gifu-u.ac.jp

Received October 30, 2020; accepted for publication March 12, 2021; published Online First on May 4, 2021. http://dx.doi.org/10.1002/onc.13772

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
INTRODUCTION

Carboplatin (CBDCA) is a key drug for the treatment of patients with thoracic malignancies [1–8]. However, CBDCA is well known to have a higher emetic risk among moderately emetogenic chemotherapy (MEC) and/or highly emetogenic chemotherapy (HEC). Chemotherapy-induced nausea and vomiting (CINV) deteriorates patients’ quality of life (QOL), impairs compliance to medications, decreases the efficacy of therapy, and reduces the likelihood of therapeutic success [9]. Therefore, the maximum prevention of CINV is vital for maintaining the patients’ QOL and continuing chemotherapy. In the latest international antiemetic guidelines, for patients with thoracic malignancies receiving CBDCA-based regimens, standard antiemetic prophylaxis for CINV is a three-drug combination comprising 5-hydroxytryptamine type-3 receptor antagonist (5-HT3 RA), dexamethasone (DEX), and neurokinin-1 receptor antagonist (NK1 RA) [10–12]. Emetogenicity is not only dependent on the type of anticancer agents but also has associated patient-related risk factors [13–16]. In particular, female sex and younger age have repeatedly been associated with an increased risk of CINV. In contrast, older age, which is in majority of the patients with thoracic malignancies, decreases the risk for CINV. In CBDCA-based chemotherapy, the complete response (CR), which was defined as the absence of emetic episodes and no administration of rescue medication for CINV, rate of treatment with first-generation 5-HT3 RA, and DEX was approximately 50% and 65% in patients with gynecological [17, 18] and thoracic [19, 20] malignancies, respectively. Moreover, the CR rate of a standard three-drug combination treatment containing aprepitant (APR) is as high as 80%–90% in patients with lung cancer [19, 21–23].

Olanzapine (OLZ) is an antipsychotic drug classified as a multiactioning, receptor-targeted agent and is a highly effective, inexpensive, and easily available antiemetic agent. Several pivotal randomized trials demonstrated that prophylactic administration of 10 mg of OLZ improved nausea prevention and the CR rate in patients who received MEC and/or HEC [24–28].

Navari et al. reported a head-to-head comparison of the effect of APR versus 10 mg of OLZ when combined with palonosetron (PALO), a second-generation 5-HT3 RA, plus DEX for HEC regimen in a phase III trial [24]. The study demonstrated that the CR rate of OLZ is comparable to that of APR. In contrast, treatment with 10 mg of OLZ showed excellent control of nausea in the delayed and overall periods than APR. This finding was also confirmed in a network meta-analysis of HEC regimens [29]. There are studies using 10 mg of OLZ for CBDCA-induced CINV, although they included fewer patients receiving CBDCA as a part of various MEC regimens [25, 30]. Moreover, patient sedation due to 10 mg of OLZ therapy may be a concern [24]. Guidelines suggest that reducing the dose of OLZ to 5 mg should be considered for patients with a risk of excessive sedation while receiving 10 mg of OLZ [10–12]. A phase II trial indicated that treatment with 5 mg and 10 mg of OLZ showed a comparable CR rate, but 5 mg of OLZ was less sedative in patients who received cisplatin-based regimens [31]. The cost per treatment cycle of 5 mg of OLZ ($7.03, $1 = ¥ 104.34 [October 29, 2020]) is less than that of APR ($111.54) and fosaprepitant ($139.40). We believe that OLZ can replace NK1 RA, because NK1 RA has high cost and clinically significant pharmacokinetic drug-drug interactions via inhibition of cytochrome P450 3A4 [32]. However, the efficacy and safety of treatment with OLZ, especially at a low dose of 5 mg, against CBDCA-induced CINV in patients with thoracic malignancies, has not been demonstrated.

Therefore, this study aimed to investigate the efficacy and safety of a three-drug combination of low dose OLZ of 5 mg combined with granisetron (GRN) and DEX in treatment of CBDCA-induced CINV in Japanese patients with thoracic malignancies.

MATERIALS AND METHODS

Study Design

This prospective study was an open-label, single-arm, multicenter, phase II trial conducted in four centers (Gifu University Hospital, Gunma Prefectural Cancer Center, Keio University Hospital, and Asahi University Hospital) in Japan, and in accordance with the Declaration of Helsinki and the Ethical Guidelines for Clinical Studies. The study was approved by the institutional review board at each participating center. This study was registered with the University Hospital Medical Information Network (umin.ac.jp/ctr/index/htm), number UMIN000031267 (principal investigators: H.I., Y.O.; primary statistician: M.S.).

Patients’ Selection

Patients with thoracic malignancies, who were scheduled to receive CBDCA (area under the curve [AUC] ≥5)-based chemotherapy, were registered in this study. Other eligibility criteria were age ≥ 20 years and < 80 years and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, 1, or 2; no symptomatic brain metastasis and carcinomatosis; no history of administration of moderately-to-highly emetogenic chemotherapy; no current use of any drugs with antiemetic activity or somnolence, such as 5-HT3 RA, NK1 RA, corticosteroids, antidepressive agents, phenothiazine tranquilizers, antihistamine drugs (premedication at paclitaxel administration was allowed), benzodiazepine agents, and so on; meeting the following standard values in general clinical tests: aspartate aminotransferase and alanine aminotransferase ≤100 U/L and total bilirubin ≤2.0 mg/dL; and provided written informed consent.

Patients were ineligible based on the following criteria: history of hypersensitivity or allergy for study drugs or similar compounds; requirement of antiemetics at enrollment; administration of opioids within 48 hours prior to enrollment; unstable angina, ischemic heart disease, cerebral hemorrhage or apoplexy, and active gastric or duodenal ulcer within 6 months prior to enrollment; having convulsive disorders requiring anticonvulsant therapy; ascites effusion requiring paracentesis; gastrointestinal obstruction; breastfeeding or expecting women or who do not wish to use contraception; having psychosis or psychiatric symptoms that interfere
Table 1. Patients’ characteristics

| Characteristics          | All Patients |
|--------------------------|--------------|
| Total number of patients | 50           |
| Age, yr                  |              |
| Median (range)           | 71 (34–79)   |
| Gender, n (%)            |              |
| Male                     | 35 (70.0)    |
| Female                   | 15 (30.0)    |
| ECOG PS, n (%)           |              |
| 0                        | 26 (52.0)    |
| 1                        | 18 (36.0)    |
| 2                        | 6 (12.0)     |
| Thoracic malignancy, n (%)|            |
| Small cell lung cancer   | 11 (22.0)    |
| Non-small cell lung cancer| 33 (66.0)  |
| Thymoma/thymic carcinoma | 5 (10.0)     |
| Others                   | 1 (2.0)      |
| Carboplatin dose, n (%)  |              |
| AUC 5 mg/mL/min          | 40 (80.0)    |
| AUC 6 mg/mL/min          | 10 (20.0)    |
| Additional anticancer drugs, n (%)|            |
| Pemetrexed               | 10 (20.0)    |
| Pemetrexed+bevacizumab   | 3 (6.0)      |
| Pemetrexed+pembrolizumab | 4 (8.0)      |
| Paclitaxel               | 3 (6.0)      |
| Paclitaxel+bevacizumab+atezorizumab | 2 (4.0) |
| paclitaxel+pembrolizumab | 2 (4.0)      |
| Nab-paclitaxel           | 2 (4.0)      |
| Nab-paclitaxel+pembrolizumab | 4 (8.0) |
| Etoposide                | 10 (20.0)    |
| Etoposide+atezorizumab   | 2 (4.0)      |
| Vinorelbine              | 5 (10.0)     |
| Tegafur/gimeracil/oteracil| 3 (6.0)    |
| Habitual alcohol consumption, n (%)|          |
| Yes                      | 25 (50.0)    |
| No                       | 25 (50.0)    |
| Motion sickness, n (%)   |              |
| Yes                      | 7 (14.0)     |
| No                       | 43 (86.0)    |
| Morning sickness, n (%)  |              |
| Yes                      | 9 (18.0)     |
| No                       | 6 (12.0)     |
| No experience, n (%)     | 19 (38.0)    |
| Unknown                  | 16 (32.0)    |

Abbreviations: AUC, area under the curve; ECOG PS, Eastern Cooperative Oncology Group performance status.

with daily life; having received abdominal or pelvic irradiation within 6 days prior to enrollment; having had diabetes mellitus; habitual smoker at enrollment; and other patients who were judged to be inappropriate for the study by the investigator.

Treatment Regimen
GRN of 1 mg was intravenously administered to patients 30 minutes before chemotherapy on day 1. DEX (9.9 mg intravenous infusion or 12 mg oral) was administered 30 minutes before chemotherapy on day 1. DEX (6.6 mg intravenous infusion or 8 mg oral) was also administered on days 2 and 3. OLZ (5 mg oral) was administered after supper for 4 days from the initial administration of CBDCA-based regimens. When paclitaxel was used as a combination of chemotherapy, the dose of DEX was increased to 19.8 mg intravenously or 20 mg orally on day 1 to prevent infusion-related hypersensitivity reactions.

Assessment Procedures
In the prestudy period, all patients’ demographic characteristics and medical data were recorded. Data were collected from patient diaries. Patients filled out the diary every 24 hours from the start of CBDCA to 120 hour periods, in which they daily reported the presence or absence of nausea, decreased appetite, somnolence, decreased concentration, and insomnia using a four-point Likert scale (none, mild, moderate, and severe). Vomiting was reported using a five-item scale (none, 1–2 times, 3–5 times, 6 times or more, and almost always), and the use of rescue medication was reported using a four-item scale (none, 1, 2 times, 2 times, and 3 times or more). After the overall assessment period (0–120 hours), patient-reported study diaries were collected. Patients were also assessed before the initiation of chemotherapy to record baseline parameters. Overall patient satisfaction with antiemetic therapy was measured on a seven-point Likert scale (very satisfied, satisfied, somewhat satisfied, rather satisfied, rather dissatisfied, dissatisfied, and very dissatisfied) after the overall assessment period (0–120 hours).

Outcomes
The primary endpoint was CR rate, which was defined as no emetic episodes and no administration of rescue medication for CINV in the overall assessment period (0–120 hours) after initiation of CBDCA-based regimen.

Secondary endpoints were CR rate in the acute period (0–24 hours), CR rate in the delayed period (24–120 hours), and complete control (CC) rate, which was defined as no emetic episodes, no use of rescue medication, and no significant nausea in the overall, acute, and delayed period. Significant nausea was defined as “moderate” and “severe” categories; a total control (TC) rate, which was defined as no emetic episodes, no use of rescue medication, and no nausea in the overall, acute, and delayed period; a time to treatment failure, which was defined as time to first emetic episode or use of rescue medication; and patient satisfaction with antiemetic therapy.

Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.

Statistical Analysis
This study hypothesized that the CR rate for 5 mg OLZ combined with GRN and DEX for AUC ≥5 mg/mL per minute of CBDCA-based regimens would be significantly higher than that
of the CR rate for standard antiemetic doublet therapy. Other trials have shown CR rates of approximately 65% [19, 20]. An improvement of the treatment effect has to be >10% to amend the guidelines of the Multinational Association of Supportive Care in Cancer/European Society for Medical Oncology 2016 [10] based on previous studies in which the CR ratio of antiemetic treatment with PALO, DEX, and APR was 80.5%–92% [19, 21–23]. We believe that an improvement of >15% in the CR rate can be clinically meaningful.

Therefore, assuming the null hypothesis of the CR rate to be ≤65% and an alternative hypothesis to be 80%, we calculated that a minimum of 48 patients were required to achieve a one-sided type I error of 0.1 and 80% of power, based on the exact binomial distribution. As some study dropouts were expected, we set the target sample size to 50 patients.

Patients’ characteristics, rate of CINV control, and treatment-related adverse events were summarized by descriptive statistics or reported as the frequency and proportion of total patients. The 80% confidence interval [CI] for the CR rate was calculated by the Clopper–Pearson exact method.

Univariate and multivariate logistic regression analyses with the backward elimination method were performed to determine the risk factors associated with CINV in the overall period. All potential explanatory variables reported in several previous studies were included as independent variables. These were patient-related risk factors, such as age, sex, ECOG PS, habitual alcohol consumption, and motion sickness [13–16]. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC). All p values were two-sided, and p < .05 was considered statistically significant.

### Results

#### Study Patients

Between February 2018 and June 2020, 51 patients were enrolled in this study. One patient was excluded from the study: very satisfied (38.0%), rather satisfied (8.0%), and dissatisfied (2.0%).

### Table 3. The incidence of nausea and vomiting over time (every 24 hours) for 5 days

| Day   | Nausea | Vomiting |
|-------|--------|----------|
| Day 1 | 0 (0)  | 0 (0)    |
| Day 2 | 1 (2.0)| 1 (2.0)  |
| Day 3 | 6 (12.0)| 2 (4.0) |
| Day 4 | 7 (14.0)| 2 (4.0) |
| Day 5 | 3 (6.0) | 0 (0)    |

Data are n (%).

#### Table 4. Treatment-related adverse events

| Symptom term  | Grade 1 | Grade 2 | Any grade |
|---------------|---------|---------|-----------|
| Dry mouth     | 31 (62.0)| 1 (2.0)| 32 (64.0) |
| Hiccups       | 20 (40.0)| 5 (10.0)| 25 (50.0) |
| Constipation  | 20 (40.0)| 16 (32.0)|36 (72.0) |
| Insomnia      | 25 (50.0)| 3 (6.0)| 28 (56.0) |
| Somnolence    | 36 (72.0)| 2 (4.0)| 38 (76.0) |
| Dizziness     | 19 (38.0)| 0 (0.0)| 19 (38.0) |

Data are n (%).

© 2021 The Authors.

The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press.
No patients reported feeling rather dissatisfied and very dissatisfied.

**DISCUSSION**

This well-designed phase II study demonstrated for the first time that a low dose of 5 mg OLZ with the addition of first-generation 5-HT₃ RA and DEX for the treatment of CBDCA-induced CINV appeared to have a beneficial effect with an acceptable safety profile in patients with thoracic malignancies.

Jordan et al. conducted a meta-analysis to evaluate the efficacy of the addition of NK₁ RA to 5-HT₃ RA and DEX combination therapy for MEC [33]. The study demonstrated that the absolute risk difference for the overall CR rate was 15%, corroborating the addition of NK₁ RA in CBDCA-based chemotherapy. In the present study, we hypothesized that 5 mg of OLZ would improve CR rate by 15% than a two-drug combination. The CR rate was 94.0%, which was 29% higher than the null hypothesis and greater than our alternative hypothesis of 80%. Thus, 5 mg of OLZ might be more effective than adding NK₁ RA because of a high CR rate of 94.0%. We also found that the highest incidence of nausea and vomiting was on days 3–4, consistent with a previous report of two- or three-drug combinations for CBDCA [34]. Therefore, it is necessary to closely monitor the onset of nausea and vomiting on days 3–4, despite administration of OLZ.

Tanaka et al. reported the efficacy of a four-drug combination consisting of OLZ (5 mg), APR, 5-HT₃ RA (GRA or PALO), and DEX for CINV induced in response to CBDCA-based chemotherapy in 33 patients with lung cancer [35]. They reported that the rates of CR, CC, and TC during the overall period were 93.9%, 90.9%, and 81.8%, respectively. The antiemetic efficacy of the present study was consistent with that of a previous study, although there were a few differences in patient characteristics (age and sex), APR, and 5-HT₃ RA (GRA or PALO). In that report, patients had average age of 75 years, and 87.9% were male. Thus, the present study had younger patients, a higher population of female sex, a three-drug combination, and administered first-generation 5-HT₃ RA in comparison with the previous study. The outcomes of the present study were comparable, although the risk of developing CINV was higher.

We previously reported the efficacy of a four-drug combination using first-generation 5-HT₃ RA in 57 patients with gynecological cancer who were treated with CBDCA-based chemotherapy [36]. The rates of CR, CC, and TC during the overall period were 78.9%, 77.2%, and 56.1%, respectively. However, these results were worse than those of the present study and that by Tanaka et al. The difference in antiemetic effects may be not due to the differences in the anticancer agents used in combination with CBDCA; for instance, paclitaxel, which was used in 96.5% of the patients with gynecological cancer, is known to have a lower emetic risk than pemetrexed, which is more commonly used in the treatment of lung cancer [37]. The risk analysis in this study failed to reveal any differences based on sex or age, but female sex and younger age have proven to be well-known patient-related risk factors [13–16]. In our previous study, all patients with gynecological cancer had a median age of 58 years. Nevertheless, somnolence and decreased concentration were found to be comparable with that in younger patients, and OLZ was considered safe for use in the elderly.

**Table 5. Risk analysis for total control and no nausea in overall phase**

| Prognostic factors              | Univariate analysis |                  |
|---------------------------------|---------------------|------------------|
|                                 | OR                  | 95% CI           | p value |
| Female                          | 0.26                | (0.050–1.337)    | .1066   |
| Age                             | 0.98                | (0.866–1.101)    | .6951   |
| ECOG PS                         | 1.27                | (0.254–6.380)    | .7694   |
| Habitual alcohol consumption    | 1.40                | (0.279–7.001)    | .6845   |
| Motion sickness                 | 0.14                | (0.022–0.841)    | .0318   |

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; OR, odds ratio.
These results suggest that triplet therapy of first-generation 5-H_{2}RA, DEX, and OLZ could be an effective, low-cost, standard treatment in elderly and/or male patients with thoracic malignancies with AUC ≥5 mg/mL per minute of CBDDA-based combination chemotherapy. Moreover, patients in limited-resource countries would be benefited with this therapy.

There were several limitations in the phase II study, despite the valuable results obtained. First, this study had an open-label and single-arm design. Second, the results were obtained only in the Japanese population and, thus, cannot be extrapolated to patients globally. Finally, patients with thoracic malignancies were predominantly elderly, although enrollment in the study was restricted to those aged less than 80 years.

**CONCLUSION**

This study demonstrated that the administration of a low dose of 5 mg of OLZ combined with GRN and DEX showed promising activity with manageable safety, suggesting that this combination appears to be a reasonable treatment approach for patients with thoracic malignancies with AUC ≥5 mg/mL per minute of CBDDA-based combination therapy. Future investigations are warranted to compare the efficacy of 5 mg of OLZ regimen to triplet standard therapy, which includes NK₁, RA in a phase III trial.

**ACKNOWLEDGMENTS**

We express our gratitude to all the patients and their families for participating in this study. We thank the members of the independent data monitoring committee: Prof. Shigehira Saji (Fukushima Medical University), Dr. Toru Mukohara (National Cancer Center Hospital East), Dr. Hideki Hayashi (Gifu Pharmaceutical University); and the independent alliance data center: Mami Matsumaru (Gifu University Hospital). We are very grateful to Yukari Ohtsuka (Gifu University Hospital) for the assistance in this study. We would like to thank Editage (www.editage.com) for English language editing and reviewing. This study was self-funded by the Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine.

This trial protocol was presented at the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology Annual Meeting 2018, Vienna, Austria, June 28–30, 2018. The protocol has been published as the following: Iihara H, Shimokawa M, Gomyo T et al. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicenter phase II trial. BMJ Open 2019;9:e028056.

**AUTHOR CONTRIBUTIONS**

Conception/design: Hirotsushi Iihara, Mototsugu Shimokawa, Yukiyoshi Fujita, Takenobu Gomyo, Yasushi Ohno

Acquisition of data: Chiemi Hirose, Takahiro Ara, Mie Kotake, Hisao Imai, Chizuru Sakai, Daizo Kaito, Jun Hakamata, Norihiko Funaguchi

Analysis and interpretation of data: Hirotsushi Iihara, Mototsugu Shimokawa, Yukiyoshi Fujita, Hitoshi Kawaoze, Chizuru Sakai, Takenobu Gomyo, Yasushi Ohno

Drafting the article or revising it critically for important intellectual content: Chizuru Sakai, Hirotsushi Iihara, Mototsugu Shimokawa, Yukiyoshi Fujita, Shinnosuke Ikemura, Koichi Minato, Akio Suzuki, Yasushi Ohno, Hiroyuki Okura

Final approval of manuscript: Chizuru Sakai, Hirotsushi Iihara, Mototsugu Shimokawa, Yukiyoshi Fujita, Shinnosuke Ikemura, Chiemi Hirose, Mie Kotake, Norihiko Funaguchi, Takenobu Gomyo, Hisao Imai, Jun Hakamata, Daizo Kaito, Koichi Minato, Takahiro Ara, Hitoshi Kawaoze, Akio Suzuki, Yasushi Ohno, Hiroyuki Okura

**DISCLOSURES**

The authors indicated no financial relationships.

**REFERENCES**

1. Wu YL, Planchard D, Lu S et al. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol 2019;30:171–210.

2. Früh M, De Ruyscher D, Popat S et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi99–105.

3. Rudin CM, Iismaia N, Hann CL et al. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 2015;33:4106–11.

4. Hanna NH, Schneider BJ, Temin S et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol 2020;38:1608–1632.

5. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 8.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/nsc1.pdf. Accessed October 12, 2020.

6. NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.2021. Available at https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed October 12, 2020.

7. NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf. Accessed October 12, 2020.

8. NCCN Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. Version 1.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/mpm.pdf. Accessed October 12, 2020.

9. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 2006;24:4472–4478.

10. Roila F, Molassiotis A, Herrstedt J et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27:v119–v133.

11. Hesketh PJ, Kris MG, Basch E et al. Antiemetics: ASCO guideline update. J Clin Oncol 2020;38:2782–2797.

12. NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020. Available at https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed October 12, 2020.

13. Hesketh PJ, Aapro M, Street JC et al. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer 2010; 18:1171–1177.

14. Warz DG, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy. Support Care Cancer 2011;19:807–813.

15. Hilarius DL, Kloege PH, van der Wall E et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study. Support Care Cancer 2012;20:107–117.

16. Sekine I, Segawa Y, Kubota K et al. Risk factors of chemotherapy-induced nausea and
vomiting: index for personalized antiemetic prophylaxis Cancer Sci 2013;104:711–717.

17. Tanioka M, Kitao A, Matsumoto K et al. A randomized, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013;109:859–865.

18. Yahata H, Kobayashi H, Sonoda K et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 2016;21:491–497.

19. Ito Y, Karayama M, Inui N et al. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 2014;84:259–264.

20. Endo J, Iihara H, Yamada M et al. A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy. Anticancer Res 2012;32:3939–3947.

21. Kusagaya H, Inui N, Karayama M et al. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer. Lung Cancer 2015;90:410–416.

22. Kitazaki T, Fukuda Y, Fukahori S et al. Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients receiving cisplatin-based or carboplatin-based chemotherapy. Support Care Cancer 2015;23:185–190.

23. Miya T, Kobayashi K, Hino M et al. Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, and aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy. Springerplus 2016;5:2080.

24. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol 2011;9:188–195.

25. Tan L, Liu J, Liu X et al. Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 2009;28:131.

26. Babu G, Saldanha SC, Kuntegowdanahalli Chinnagiriyappa L et al. The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: A pilot study from South India. Chemother Res Pract 2016;2016:3439707.

27. Wang X, Wang L, Wang H et al. Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer. Cell Biochem Biophys 2015;72:471–473.

28. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134–142.

29. Zhang Z, Zhang Y, Chen G et al. Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: A network meta-analysis. The Oncologist 2018;23:603–616.

30. Navari RM, Einhorn LH, Loehrer PJ Jr et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study. Support Care Cancer 2007;15:1285–1291.

31. Yanai T, Iwasa S, Hashimoto H et al. A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018;23:382–388.

32. Patel P, Leeder JS, Piquette-Miller M et al. Aprepitant and fosaprepitant drug interactions: A systematic review. Br J Clin Pharmacol 2018;83:2148–2162.

33. Jordan K, Blätttermann L, Hinke A et al. Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?: Systematic review and meta-analysis. Support Care Cancer 2018;26:21–32.

34. Ihara H, Shimokawa M, Hayashi T et al. A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan. The Oncologist 2020;25:e373–e380.

35. Tanaka K, Inui N, Karayama M et al. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 2019;84:147–153.

36. Ihara H, Shimokawa M, Hayasaki Y et al. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron, and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study. Gynecol Oncol 2020;156:629–635.

37. Hayashi T, Shimokawa M, Matsuo K et al. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis. BMC Cancer 2021;21:74.